Overview
NervGen Pharma is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics, including lead candidate NVG-291, a subcutaneously administered peptide targeting spinal cord injury in Phase 1b/2a trials. NVG-291 promotes nervous system repair by countering chondroitin sulfate proteoglycans (CSPGs) to enable axonal regeneration, neuroplasticity, and remyelination. The company is also advancing NVG-300 in preclinical models for neurotraumatic and neurologic conditions, supported by U.S. Department of Defense funding.
Frequently asked questions
- What is NervGen's lead product candidate and its development stage?
- NVG-291 is a first-in-class neuroreparative peptide in Phase 1b/2a clinical trials (CONNECT SCI Study) for chronic spinal cord injury, demonstrating improved function and quality of life.
- What therapeutic areas does NervGen target?
- Primary focus is spinal cord injury, with preclinical work on traumatic brain injury, traumatic hearing loss, ischemic stroke, and potential in multiple sclerosis via NVG-291 and NVG-300.
- What is the mechanism of action for NVG-291?
- NVG-291 relieves inhibitory effects of CSPGs to promote axonal regeneration, neuroplasticity, remyelination, and functional recovery such as locomotion and bladder control in preclinical models.